These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Darolutamide in hormone-sensitive and castration-resistant prostate cancer. Palmieri VE; Roviello G; D'Angelo A; Casadei C; De Giorgi U; Giorgione R Expert Rev Clin Pharmacol; 2021 May; 14(5):535-544. PubMed ID: 33685318 [No Abstract] [Full Text] [Related]
4. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Fizazi K; Smith MR; Tombal B Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098 [TBL] [Abstract][Full Text] [Related]
5. [A new androgen receptor antagonist : Darolutamide for patients with non-metastatic castration-resistant prostate cancer]. Kesch C; Hadaschik BA Urologe A; 2019 Oct; 58(10):1217-1218. PubMed ID: 31471641 [No Abstract] [Full Text] [Related]
6. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH Molecules; 2020 May; 25(10):. PubMed ID: 32456317 [TBL] [Abstract][Full Text] [Related]
7. An up-to-date evaluation of darolutamide for the treatment of prostate cancer. Moussa M; Lazarou L; Dellis A; Abou Chakra M; Papatsoris A Expert Opin Pharmacother; 2021 Mar; 22(4):397-402. PubMed ID: 33135506 [No Abstract] [Full Text] [Related]
8. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201). Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578 [TBL] [Abstract][Full Text] [Related]
9. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial. Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777 [TBL] [Abstract][Full Text] [Related]
10. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer]. Zhang F; Lu YP Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306 [TBL] [Abstract][Full Text] [Related]
11. Cases in the management of prostate cancer: the addition of darolutamide to androgen deprivation therapy and docetaxel in a 55-year-old man with metastatic hormone-sensitive prostate cancer. Crawford ED Clin Adv Hematol Oncol; 2022 Jul; 20 Suppl 14(7):1-8. PubMed ID: 35905311 [No Abstract] [Full Text] [Related]
12. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. Fizazi K; Shore N; Tammela TL; Ulys A; Vjaters E; Polyakov S; Jievaltas M; Luz M; Alekseev B; Kuss I; Le Berre MA; Petrenciuc O; Snapir A; Sarapohja T; Smith MR; N Engl J Med; 2020 Sep; 383(11):1040-1049. PubMed ID: 32905676 [TBL] [Abstract][Full Text] [Related]
16. [Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient?]. Vis AN; van Moorselaar RJA Ned Tijdschr Geneeskd; 2019 Nov; 163():. PubMed ID: 32073798 [TBL] [Abstract][Full Text] [Related]
17. Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide added to leuprolide in a 73-year-old patient. Landau DA Clin Adv Hematol Oncol; 2022 Jun; 20 Suppl 10(6):1-8. PubMed ID: 35772002 [No Abstract] [Full Text] [Related]
18. Darolutamide: First Approval. Markham A; Duggan S Drugs; 2019 Nov; 79(16):1813-1818. PubMed ID: 31605368 [TBL] [Abstract][Full Text] [Related]
19. Darolutamide (ODM-201) for the treatment of prostate cancer. Shore ND Expert Opin Pharmacother; 2017 Jun; 18(9):945-952. PubMed ID: 28490267 [TBL] [Abstract][Full Text] [Related]